Department of Medical and Surgical Sciences and Advanced Technologies "GF Ingrassia", University of Catania, Via S. Sofia, 87, 95123 Catania, Italy.
Department of General Surgery and Medical-Surgical Specialties, University of Catania, Via Plebiscito, 628, 95124 Catania, Italy.
Biomed Res Int. 2019 Jan 15;2019:1602539. doi: 10.1155/2019/1602539. eCollection 2019.
The burden of chronic kidney disease is dramatically rising, making it a major public health concern worldwide. Kidney transplantation is now the best treatment for patients with end-stage renal disease. Although kidney transplantation may improve survival and quality of life, its long-term results are hampered by immune- and/or non-immune-mediated complications. Thus, the identification of transplanted patients with a higher risk of posttransplant complications has become a big challenge for public health. However, current biomarkers of posttransplant complications have a poor predictive value, rising the need to explore novel approaches for the management of transplant patient. In this review we summarize the emerging literature about DNA methylation in kidney transplant complications, in order to highlight its perspectives toward biomarker identification. In the forthcoming future the monitoring of DNA methylation in kidney transplant patients could become a plausible strategy toward the prevention and/or treatment of kidney transplant complications.
慢性肾脏病的负担正在显著上升，成为全球主要的公共卫生关注点。肾脏移植是目前终末期肾病患者的最佳治疗方法。尽管肾脏移植可以提高生存率和生活质量，但免疫和/或非免疫介导的并发症会阻碍其长期效果。因此，识别具有更高移植后并发症风险的移植患者已成为公共卫生的一大挑战。然而，目前移植后并发症的生物标志物预测价值较差，因此需要探索新的方法来管理移植患者。在这篇综述中，我们总结了关于肾脏移植并发症中 DNA 甲基化的新出现的文献，以强调其在确定生物标志物方面的前景。在未来，监测肾脏移植患者的 DNA 甲基化可能成为预防和/或治疗肾脏移植并发症的一种可行策略。
